

Boston Scientific Announces Completion of FDA Inspection of Minnesota Drug-Eluting Stent Manufacturing Facility

(February 6, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced that an inspection team from the U.S. Food and Drug Administration (FDA) has completed its inspection of the Company's drug-eluting stent manufacturing facility in Maple Grove, Minnesota. The team reported no observations during the inspection and indicated it intends to recommend to the FDA that the Maple Grove facility be approved to manufacture the TAXUSTM Express²TM paclitaxel-eluting coronary stent system for the U.S. market. The inspection was the second of two by the FDA of Boston Scientific's drug-eluting stent manufacturing facilities. In January, an FDA team inspected the Company's drug-eluting stent manufacturing facility in Galway, Ireland and reported no observations.

"This brings us an important step closer to approval of the TAXUS system in the U.S.," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "I want to congratulate our Maple Grove team for this flawless inspection. I am very proud that the FDA inspectors reported no observations at Maple Grove or Galway. This further demonstrates our commitment to quality in every aspect of the TAXUS program. Based on these two outstanding inspections, I am confident the FDA will approve the TAXUS system this quarter."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and introduction, clinical trials, regulatory approvals, competitive offerings, litigation, operational improvements, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.

<https://news.bostonscientific.com/completion-fda-inspection-des-manufacturing>